Ratings by Raymond James (Gary Nachman)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/24/2025 | Achieve Life Sciences | ACHV | Maintain | Strong Buy (N/A) |
|
Details | ||
| 11/3/2025 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 10/17/2025 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 10/9/2025 | Ionis Pharmaceuticals | IONS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/25/2025 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 8/13/2025 | Veru, Inc. | VERU | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2025 | INmune Bio Inc. | INMB | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/1/2025 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 7/31/2025 | Ionis Pharmaceuticals | IONS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 7/31/2025 | LENZ Therapeutics Inc | LENZ | Maintain | Outperform (N/A) |
|
Details | ||
| 6/30/2025 | INmune Bio Inc. | INMB | Downgrade | Market Perform (Outperform) |
5.33 (1.42) |
-73.36% | Details | |
| 5/13/2025 | Aquestive Therapeutics | AQST | Maintain | Outperform (N/A) |
|
Details | ||
| 4/8/2025 | Pacira Pharmaceuticals | PCRX | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/31/2025 | INmune Bio Inc. | INMB | Maintain | Outperform (N/A) |
|
Details | ||
| 2/20/2025 | Ionis Pharmaceuticals | IONS | Maintain | Strong Buy (N/A) |
|
Details | ||
| 2/12/2025 | INmune Bio Inc. | INMB | Maintain | Outperform (N/A) |
|
Details | ||
| 2/3/2025 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 1/28/2025 | Abbvie | ABBV | Maintain | Outperform (N/A) |
|
Details | ||
| 1/10/2025 | Pacira Pharmaceuticals | PCRX | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/27/2024 | LENZ Therapeutics Inc | LENZ | New Coverage | Outperform (N/A) |
21.57 (5.75) |
-73.34% | Details | |
| 9/27/2024 | Achieve Life Sciences | ACHV | New Coverage | Strong Buy (N/A) |
4.38 (5.01) |
14.38% | Details | |
| 8/19/2024 | Sol Gel Technologies Ltd. | SLGL | Downgrade | Outperform (Strong Buy) |
0.42 (71.26) |
16866.67% | Details | |
| 8/12/2024 | Pacira Pharmaceuticals | PCRX | Downgrade | Market Perform (Outperform) |
22.36 (23.51) |
5.14% | Details | |
| 7/10/2024 | Bausch & Lomb Corp. | BLCO | New Coverage | Outperform (N/A) |
15.33 (15.24) |
-0.59% | Details | |
| 3/27/2024 | Amgen | AMGN | New Coverage | Market Perform (N/A) |
281.77 (347.01) |
23.15% | Details | |
| 3/27/2024 | Scholar Rock | SRRK | New Coverage | Strong Buy (N/A) |
15.00 (37.09) |
147.27% | Details | |
| 3/27/2024 | Aquestive Therapeutics | AQST | New Coverage | Outperform (N/A) |
4.06 (5.03) |
23.89% | Details | |
| 3/27/2024 | Veru, Inc. | VERU | New Coverage | Outperform (N/A) |
0.61 (3.04) |
398.36% | Details | |
| 12/19/2023 | Pacira Pharmaceuticals | PCRX | New Coverage | Outperform (N/A) |
30.85 (22.36) |
-27.52% | Details | |
| 8/11/2023 | Sol Gel Technologies Ltd. | SLGL | Maintain | Strong Buy (N/A) |
|
Details | ||
| 8/10/2023 | ADMA Biologics | ADMA | Maintain | Strong Buy (N/A) |
|
Details | ||
| 7/19/2023 | ADMA Biologics | ADMA | New Coverage | Strong Buy (N/A) |
3.57 (8.12) |
127.45% | Details | |
| 7/19/2023 | Sol Gel Technologies Ltd. | SLGL | New Coverage | Strong Buy (N/A) |
3.01 (71.26) |
2267.44% | Details |
